Diabetic neuropathies. Current concepts in prevention and treatment
- PMID: 3530705
- DOI: 10.2165/00003495-198632030-00004
Diabetic neuropathies. Current concepts in prevention and treatment
Abstract
Diabetic nerve damage leads to a wide variety of unpleasant problems: painful sensations, muscle weakness, numb feet predisposing to ulcers, impotence, and a series of distressing effects due to autonomic dysfunction. At present, there is no single effective treatment for the many clinical syndromes--each of which may well have a different cause. Improved blood glucose control must remain the first line of treatment, hopefully to improve nerve structure and function but also to raise the pain threshold. A variety of sedatives and analgesics may also help some patients. Inhibition of the enzyme aldose reductase with resultant interference with neural sorbitol and myo-inositol metabolism would seem to have a good theoretical basis in therapy, and detailed results of long term clinical trials of aldose reductase inhibitors such as sorbinil and tolrestat are awaited with interest. Their role in the future could be more important in prevention of nerve damage than in attempting to reverse gross end-stage nerve destruction. In diabetic subjects with loss of pain sensation in the foot due to neuropathy or in the more advanced state of foot ulceration, intensive educational and clinical efforts should be exerted to prevent this distressing and common problem. In the future, a more detailed understanding of the biochemical abnormalities occurring in nerves and their effect on nerve function, structure and vasculature may lead to more satisfactory and logical treatments for this the commonest single complication of diabetes.
Similar articles
-
Aldose reductase inhibitors and late complications of diabetes.Drugs. 1986;32 Suppl 2:43-55. doi: 10.2165/00003495-198600322-00010. Drugs. 1986. PMID: 3098544 Review.
-
[Diabetic somatic polyneuropathy. Pathogenesis, clinical manifestations and therapeutic concepts].Fortschr Neurol Psychiatr. 2000 Jun;68(6):278-88. doi: 10.1055/s-2000-11535. Fortschr Neurol Psychiatr. 2000. PMID: 10923253 Review. German.
-
Sorbitol, myo-inositol and sodium-potassium ATPase in diabetic peripheral nerve.Drugs. 1986;32 Suppl 2:6-14. doi: 10.2165/00003495-198600322-00004. Drugs. 1986. PMID: 3024950 Review.
-
[Therapy of diabetic neuropathy].Przegl Lek. 2003;60(3):167-9. Przegl Lek. 2003. PMID: 14575019 Review. Polish.
-
Pathogenesis of diabetic neuropathy: role of altered phosphoinositide metabolism.Crit Rev Neurobiol. 1989;5(2):143-219. Crit Rev Neurobiol. 1989. PMID: 2561904 Review.
Cited by
-
Aldose reductase inhibitors and late complications of diabetes.Drugs. 1986;32 Suppl 2:43-55. doi: 10.2165/00003495-198600322-00010. Drugs. 1986. PMID: 3098544 Review.
-
Clinical experience with cyclandelate in insulin-dependent diabetic patients with neuropathy.Drugs. 1987;33 Suppl 2:125-30. doi: 10.2165/00003495-198700332-00023. Drugs. 1987. PMID: 3304951 Clinical Trial.
-
Use of ion channel blockers in the exploration of possible mechanisms involved in the myopathy of diabetic mice.Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):311-8. doi: 10.1007/BF00169161. Naunyn Schmiedebergs Arch Pharmacol. 1993. PMID: 7694160
-
The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.Drugs Aging. 1995 Jan;6(1):9-28. doi: 10.2165/00002512-199506010-00002. Drugs Aging. 1995. PMID: 7696781 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical